Cornelia Van Duijn

Dr. Cornelia Van Duijn

Population Health Department, University of Oxford, Oxford, UK

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2022 in Nature Genetics
Verified
Journal Article
Open access
PDF file
CBCéline Bellenguez
Céline Bellenguez
FKFahri Küçükali
Fahri Küçükali
IJIris E. Jansen
Iris E. Jansen
LKLuca Kleineidam
Luca Kleineidam
SMSonia Moreno-Grau
Sonia Moreno-Grau
JLJean-Charles Lambert
Jean-Charles Lambert
Characterization of the genetic landscape of Alzheimer’s disease (AD) and related dementias (ADD) provides a unique opportunity for a better understanding of the associated pathophysiological processes. We performed a two-stage genome-wide association study totaling 111,326 clinically diagnosed/‘proxy’ AD cases and 677,663 controls. We found 75 risk loci, of which 42 were new at the time of analysis. Pathway enrichment analyses confirmed the involvement of amyloid/tau pathways and highlighted microglia implication. Gene prioritization in the new loci identified 31 genes that were suggestive of new genetically associated processes, including the tumor necrosis factor alpha pathway through the linear ubiquitin chain assembly complex. We also built a new genetic risk score associated with the risk of future AD/dementia or progression from mild cognitive impairment to AD/dementia. The improvement in prediction led to a 1.6- to 1.9-fold increase in AD risk from the lowest to the highest decile, in addition to effects of age and the APOE ε4 allele.

18 January 2021 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
AKAlexander Kurilshikov
Alexander Kurilshikov
CGCarolina Medina Gomez
Carolina Medina Gomez
RBRodrigo Bacigalupe
Rodrigo Bacigalupe
DRDjawad Radjabzadeh
Djawad Radjabzadeh
JWJun Wang
Jun Wang
AZAlexandra Zhernakova
Alexandra Zhernakova

23 November 2021 in Nature Reviews Neuroscience
Verified
Journal Article
Closed access
PDF file
GFGiovanni B. Frisoni
Giovanni B. Frisoni
DADaniele Altomare
Daniele Altomare
DTDietmar Rudolf Thal
Dietmar Rudolf Thal
FRFederica Ribaldi
Federica Ribaldi
RKRik van der Kant
Rik van der Kant
BDBruno Dubois
Bruno Dubois

6 December 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
DRDjawad Radjabzadeh
Djawad Radjabzadeh
JBJos A. Bosch
Jos A. Bosch
AUAndré G. Uitterlinden
André G. Uitterlinden
AZAeilko H. Zwinderman
Aeilko H. Zwinderman
MIM. Arfan Ikram
M. Arfan Ikram
NANajaf Amin
Najaf Amin
Depression is one of the most poorly understood diseases due to its elusive pathogenesis. There is an urgency to identify molecular and biological mechanisms underlying depression and the gut microbiome is a novel area of interest. Here we investigate the relation of fecal microbiome diversity and composition with depressive symptoms in 1,054 participants from the Rotterdam Study cohort and validate these findings in the Amsterdam HELIUS cohort in 1,539 subjects. We identify association of thirteen microbial taxa, including genera Eggerthella, Subdoligranulum, Coprococcus, Sellimonas, Lachnoclostridium, Hungatella, Ruminococcaceae (UCG002, UCG003 and UCG005), LachnospiraceaeUCG001, Eubacterium ventriosum and Ruminococcusgauvreauiigroup, and family Ruminococcaceae with depressive symptoms. These bacteria are known to be involved in the synthesis of glutamate, butyrate, serotonin and gamma amino butyric acid (GABA), which are key neurotransmitters for depression. Our study suggests that the gut microbiome composition may play a key role in depression.

8 August 2024 in Nature Medicine
Verified
Journal Article
Open access
PDF file
MAM. Austin Argentieri
M. Austin Argentieri
SXSihao Xiao
Sihao Xiao
DBDerrick Bennett
Derrick Bennett
LWLaura Winchester
Laura Winchester
ANAlejo J. Nevado-Holgado
Alejo J. Nevado-Holgado
Cornelia Van DuijnCornelia Van Duijn
Cornelia Van Duijn
Circulating plasma proteins play key roles in human health and can potentially be used to measure biological age, allowing risk prediction for age-related diseases, multimorbidity and mortality. Here we developed a proteomic age clock in the UK Biobank (n = 45,441) using a proteomic platform comprising 2,897 plasma proteins and explored its utility to predict major disease morbidity and mortality in diverse populations. We identified 204 proteins that accurately predict chronological age (Pearson r = 0.94) and found that proteomic aging was associated with the incidence of 18 major chronic diseases (including diseases of the heart, liver, kidney and lung, diabetes, neurodegeneration and cancer), as well as with multimorbidity and all-cause mortality risk. Proteomic aging was also associated with age-related measures of biological, physical and cognitive function, including telomere length, frailty index and reaction time. Proteins contributing most substantially to the proteomic age clock are involved in numerous biological functions, including extracellular matrix interactions, immune response and inflammation, hormone regulation and reproduction, neuronal structure and function and development and differentiation. In a validation study involving biobanks in China (n = 3,977) and Finland (n = 1,990), the proteomic age clock showed similar age prediction accuracy (Pearson r = 0.92 and r = 0.94, respectively) compared to its performance in the UK Biobank. Our results demonstrate that proteomic aging involves proteins spanning multiple functional categories and can be used to predict age-related functional status, multimorbidity and mortality risk across geographically and genetically diverse populations.

7 June 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
IRItziar de Rojas
Itziar de Rojas
SMSonia Moreno-Grau
Sonia Moreno-Grau
NTNiccolo Tesi
Niccolo Tesi
BGBenjamin Grenier-Boley
Benjamin Grenier-Boley
VAVictor Andrade
Victor Andrade
ARAgustín Ruiz
Agustín Ruiz
Genetic discoveries of Alzheimer’s disease are the drivers of our understanding, and together with polygenetic risk stratification can contribute towards planning of feasible and efficient preventive and curative clinical trials. We first perform a large genetic association study by merging all available case-control datasets and by-proxy study results (discovery n = 409,435 and validation size n = 58,190). Here, we add six variants associated with Alzheimer’s disease risk (near APP, CHRNE, PRKD3/NDUFAF7, PLCG2 and two exonic variants in the SHARPIN gene). Assessment of the polygenic risk score and stratifying by APOE reveal a 4 to 5.5 years difference in median age at onset of Alzheimer’s disease patients in APOE ɛ4 carriers. Because of this study, the underlying mechanisms of APP can be studied to refine the amyloid cascade and the polygenic risk score provides a tool to select individuals at high risk of Alzheimer’s disease.